Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?

Abstract

Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.

http://bit.ly/2XdD3fI